Abstract
The earth is a unity for influenza A virus in a manner not yet found for any other parasite (Hope-Simpson 1979). Epidemics occur in all inhabited parts of the globe regardless of latitude, longitude, altitude climate, rainfall, temperature, humidity, race and sex (Stuart-Harris & Schild 1976; Pereira 1979 Stuart-Harris 1981). Influenza A is the classic pandemic virus infection of humans, but influenza B virus can also cause sharp outbreaks resulting in significant mortality. Mortality data from 1200 million people living in 88 of the 160 or so WHO member states (approximately one quarter of the world’s population) show that more than two million deaths from acute respiratory disease occur annually (reviewed by Lennette, 1981, see also Table 1) and that the majority of acute viral respiratory disease is attributed to viruses of 5 families. Influenza A and B viruses cause a significant number of these deaths.
Keywords
- Influenza Virus
- Influenza Vaccine
- Acute Respiratory Disease
- Lower Respiratory Tract Disease
- Amantadine Hydrochloride
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
ALEXANDROVA, G.I. & SMORODINTSEV, A.A. (1965). Obtaining of an additionally attenuated vaccinating cryophilic influenza strain. Rev. Roum. Inframicrobiol., 2, 179–186.
ALLING, D.W., BLACKWELDER, W.C. & STUARTHARRIS, C.H. (1981). A study of excess mortality during influenza epidemics in the United States 1968–1976. Am. J. Epidemiol., 113, 30–43.
AOKI, F.Y., SITAR, D.S. & OGILVIE, R.I. (1979). Amantadine kinetics in healthy young subjects after long-term dosing. Clin. Pharmac. Ther., 6, 729–736.
BEARE, A.S. (1982). (ed.) Basic and Applied Influenza Research, Cleveland, Ohio: CRC Press.
BLAAS, D., PATZELT, E. & KUECHLER, E. (1982). Cap recognizing protein of influenza virus. Virology, 116, 339–348.
BLEIDNER, W.E., HARMON, J.B., NEWES, W.E., LYNES, T.E. & HERMANN, E.C. (1965). Absorption, distribution, and excretion of amantadine hydrochloride. J. Pharmac. exp. Ther., 150, 484–490.
BUKRINSKAYA, A.G., VORKUNOVA, N.K. & NARMANBETOVA, R.A. (1980). Rimantadine hydrochloride blocks the second step of influenza virus uncoating. Arch. Virol., 66, 275–282.
CENTERS FOR DISEASE CONTROL (1982). Influenza vaccine efficacy in nursing home outbreaks reported during 1981–1982. MMWR, 31, 190.
CHANOCK, R.M. (1982). New Opportunities for development of safe effective live virus vaccines. Yale J. biol. Med., 55, 361–367.
CHRETIEN, J., HOLLAND, W., MACKLEM, P., MURRAY, J. & WOOLCOCK, A. (1984). Acute respiratory infections in children: a global health problem. N. Engl. J. Med., 982–984.
CLOAD, P.A. & HUTCHINSON, D.W. (1983). The inhibition of the RNA polymerase activity of influenza virus A by pyrophosphate analogues. Nucl. Acid. Res., 11, 5621–5628.
DAVIES, W.L., GRUNERT, R.R., HAFF, R.F., McGAHEN, J.W., NEUMAYER, E.M., PAULSHOCK, M. & 4 OTHERS (1964). Science, 144, 862–863.
DOLIN, R., REICHMAN, R.C., MADORE, H.P., MAYNARD, R., LINTON, P.M. & WEBBER-JONES, J. (1982). A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. New. Engl. J. Med., 307, 580–584.
DOLIN, R., BETTS, R.F., TREENER, J.J., ERB, S.M., O’BRIEN, D.H., ROTH, F.K., MILLER, P., DUFFY, P. (1983). Rimantadine prophylaxis of influenza A in elderly. Proceedings of the23rd ICAAC, October 1983, Abstract no.691, p.210.
DOUGLAS, R.G., Jr (1980). Amantadine: Should it be used as an antiviral? In Controversies in therapeutics, Lasagna, L. (ed.) pp.271–280, Philadelphia: W.-B. Saunders.
EATON, M.D., LOW, I.E., SCALA, A.R. & URETSKY, S. (1962). Inhibition by ammonium ion of the growth of influenza virus in chorio allantoic tissue. Virology, 118, 102–108.
EMTAGE, J.S., TACON, W.C.A., CATLIN, G.H., JENKINS, B., POSTER, A.G. & CAREY, N.H. (1980). Influenza antigenic determinants are expressed from haemagglutinin genes cloned in E. coli. Nature, 283, 171–174.
FIELDS, S., WINTER, G. & BROWNLEE, G.G. (1981). Structure of the neuraminidase gene in human influenza virus A/PR/8/34. Nature, 290, 213.
GALBRAITH, A.W., OXFORD, J.S., SCHILD, G.C. & WATSON, G.I. (1969). Protective effect of 1-adamantamine hydrochloride on influenza A2 infections in the family environment. Lancet, 1026–1028.
GALASSO, G.J., BEKTIMIROV, T.A., DOUGLAS, R.G., KRYLOV, V.F. & OXFORD, J.S. (1984). Current status of amantadine and rimantadine as anti influenza agents: memorandum of a WHO meeting. Bull. Wld Hlth Org. (in press).
GETHING, M.J. & SAMBROOK, J. (1982). Construction of influenza haemagglutinin genes that code for intracellular and secreted forms of the protein. Nature, 300, 598–603.
GOODMAN, R.A., ORENSTEIN, W.A., MUNRO, T.F., SMITH, S.C. & SIKES, R.K. (1982). Impact of influenza A in a nursing home. J. Am. med. Ass., 247, 1451–1453.
GREEN, N., ALEXANDER, H., OLSON, A., ALEXANDER, S., SHINNICK, T.M., SUTCLIFFE, J.G. & LERNER, R.A. (1982). Immunogenic structure of the influenza virus haemagglutinin. Cell, 28, 477–487.
GRUNERT, R.R., McGAHAN, J.W. & DAVIES, W.L. (1965). The in vivo antiviral activity of 1-adamantanamine (amantadine). 1. Prophylactic and therapeutic activity against influenza viruses. Virology, 26, 262–269.
HAYDEN, F.G., COTE, K.M. & DOUGLAS, R.G. (1980). Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob. Ag. Chemo., 17, 865–870.
HAYDEN, F.G., HOFFMAN, H.E. & SPYKER, D.A. (1983). Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob. Ag. Chemo., 23, 458–464.
HEIDER, H., ADAMCZCK, B., PRTESBER, H.W., SCHROEDER, C., FELDBLUM, R. & INDULEN, M.K. (1981). Occurrence of amantadine and rimantadine resistant influenza A virus strains during the 1980 epidemic. Acta. Virol., 25, 395–400.
HELGSTRAND, E. & OBERG, B.O. (1978). Antiviral screening based on cell-free polymerase models and a new selective inhibitor. Current Chemotherapy.
HO, P.P.K. & WALTERS, C.P. (1971). Inhibitors of influenza virus induced RNA polymerase. Ann. N.Y. Acad. Sci., 133, 438.
HOFFMAN, C.E. (1980). Amantadine HCl and related compounds. In Carter, W.A. (ed.) Selective inhibitors of viral functions, pp. 199–211, Cleveland, Ohio: CRC Press.
HOPE-SIMPSON, R.E. (1979). Epidemic mechanisms of Type A influenza. J. Hyg., 83, 11–26.
HORNICK, R.B., TOGO, Y., MAHLER, S. & IEZZONI, D.G. (1970). Evaluation of amantadine hydrochloride in the treatment of A2 influenzal disease. Ann. N.Y. Acad. Sci., 173 (1), 10–19.
INDULEN, M.K. & KALNINYA, V.A. (1980). Studies on the Antiviral effect and the mode of action of the anti-influenza compound rimantadine. In Development in Antiviral Therapy, Collier, L.H. & Oxford, J.S. (eds) pp. 107–118, London: Academic Press.
JACKSON, G.C., MULDOON, R.L. & AKERS, L.W. (1963). Serological evidence for prevention of influenzal infection in volunteers by an anti-influenzal drug adamantanamine hydrochloride. Antimicrob. Ag. Chemo., 703–707.
KILBOURNE, E.D. (1969). Future influenza vaccines and the use of genetic recombinants. Bull. Wld Hlth Org., 41, 643–645.
KNIGHT, V., McCLUNG, H.W., WILSON, S.Z. et al. (1981). Ribavirin small-particle aerosol treatment of influenza. Lancet, ii, 945–949.
LENNETTE, E.M. (1981). Viral respiratory diseases: Vaccines and antivirals. Bull. Wld. Hlth. Org., 59, 305–324.
MAEDA, T., KAWASAKI, K. & OHNISHI, S.-I. (1981). Interaction of influenza virus haemagglutinin with target membrane lipids is a key step in virus-induced hemolysis and fusion at pH 5.2 Proc. natn. Acad. Sci. U.S.A., 78, 4133.
MAASSAB, H.F. (1967). Adaptation and growth characteristics of influenza virus at 25°C. Nature, 213, 612–614.
McCLUNG, H.W., KNIGHT, V., GILBERT, B.E., WILSON, S.Z., QUARLES, J.M. & DIVINE, ?. (1983). Ribavirin aerosol treatment of influenza B virus infection. J. Am. med. Ass., 249, 2671–2674.
MCCAULEY, J.W. & MAHY, B.W.J. (1983). Structure and function of the influenza virus genome. Biochem. J., 211, 281.
MONTO, A.S., GUNN, R.A., BANDYK, M.G. & KING, C. (1979). Prevention of Russian Influenza by Amantadine. J.Am.med.Ass., 241, 1003–1007.
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES. (1980). Amantadine: does it have a role in the prevention and treatment of influenza A. A National Institutes of Health Consensus Development Conference. Ann. Intern. Med., 92, 256–258.
OXFORD, J.S. (1975). Inhibition of the replication of influenza A and B viruses by a nucleoside analogue (ribavirin). J. gen. Virol., 28, 409–414.
OXFORD, J.S. (1983). Amantadine — problems with its clinical usage. In Problems of antiviral chemotherapy. Stuart-Harris, C.H. & Oxford, J.S. (eds.) p. 231, London: Academic Press.
OXFORD, J.S. & GALBRAITH, A. (1980). Antiviral activity of amantadine: a review of laboratory and clinical data. Pharmac. Rev., 11, 181–262.
OXFORD, J.S., HAAHEIM, L.R., SLEPUSHKIN, A., WERNER, J., KUWERT, E. & SCHILD, G.C. (1981). Strain specificity of serum antibody to the haemagglutinin of influenza A (H3N2) viruses in children following immunization or natural infection. J. Hyg. Camb., 86, 17.
OXFORD, J., LOGAN, I.S. & POTTER, C.W. (1970). In vivo selection of an influenza A 2-strain resistant to amantadine. Nature, 226, 82–83.
OXFORD, J.S., McGEOCH, D.J., SCHILD, G.C. & BEARE, A.S. (198(. Analysis of virion RNA segments and polypeptides of influenza A virus recombinants of defined virulence. Nature, 273, 778–779.
OXFORD, J.S. & PERRIN, D.D. (1974). Inhibition of the particle associated RNA dependent RNA polymerase activity of influenza viruses by chelating agents. J. gen. Virol., 23, 59.
PATRIARCA, P.A., KATER, N.A., KENDAL, A.P., BREGMAN, D.J., SMITH, J.D. & SIKES, R.K. (1983). Safety of prolonged administration of rimantadine hydrochloride in the prophylaxis of influenza A infections in nursing homes. Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, Nevada, October 1983.
PALESE, P. & SCHULMAN, J.L. (1977). Inhibitors of viral neuraminidase as potential antiviral drugs. In Chemoprophylaxis and Virus Infections of the Respiratory Tract, vol. I, p. 689 Oxford, J.S. (ed.) Cleveland, Ohio: CRC Press.
PAYLER, D.K. & PURDHAM, P.A. (1984). Influenza A prophylaxis with amantadine in a boarding school. Lancet, i, 502–504.
PEREIRA, M.S. (1979). Global surveillance of influenza. Br. med. Bull., 35, 9–14.
PERRIN, D.D. (1977). In Chemoprophylaxis and Virus Infections of the Respiratory Tract vol. II. Oxford, J.S. (ed.) Cleveland, Ohio: CRC Press.
PERRIN, D.D. & STUNZI, H. (1980). Viral chemotherapy: antiviral actions of metal ions and metal chelating agents. Pharmac. Ther., 12, 255–297.
POTTER, C.W., PHAIR, J.P., VODINELICH, L., FENTON, R. & JENNINGS, R. (1976). Antiviral, immunosuppressive and anti-tumour effects of ribavirin. Nature, 259, 496–497.
RICHARDSON, C.D., SCHEID, A. & CHOPPIN, P.W. (1980). Specific inhibition of paramyxovirus and Myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-termini of the Fl or HA2 viral polypeptides. Virology, 105, 205–222.
RICHMAN, D.D. & MURPHY, B.R. (1979). The association of the temperature sensitive phenotype with viral attenuation in animals and humans: implication for the development and use of live virus vaccines. Rev. Infect. Dis., 1, 413–473.
RICHMAN, D.D., YAZAKI, P. & HOSTETLER, K.Y. (1981). The intracellular distribution and antiviral activity of amantadine. Virology, 112, 81–90.
SCHILD, G.C., OXFORD, J.S., JONG, J. DE. & WEBSTER, R.G. (1983). Evidence for host cell selection of antigenic variants of influenza B virus. Nature, 303, 706–709.
SCHULMAN, J.L. & KILBOURNE, E.D. (1965). Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. J. Bact., 89, 170–174.
SCHWAB, R.S., POSKANZER, D.C., ENDLAND, A.C. & YOUNG, R.R. (1972). Amantadine in Parkinson’s disease — review of more than two years’ experience. J. Am. med. Ass., 222, 792–795.
SELBY, P. (ed.) (1976). Influenza: virus, vaccines and strategy. New York: Academic Press.
SIDWELL, R.W., HUFFMAN, J.H., KHARE, G.P., ALLEN. L.B., WITKOWSKI, J.T. & ROBINS, R.K. (1972). Broadspectrum antiviral activity of Virazole: 1-B-Dribofuranosyl-1,2,4-triazole-3-carboxamide. Science, 177, 705–706.
SMITH, R.A. & KIRKPATRIC, W. (eds.) (1980). Ribavirin: a broad spectrum antiviral agent, pp. 59–71, New York: Academic Press.
STRIDH, S., HELGSTRAND, E., LANNEROE, B., MISIORNY, A., STENING, G. & OBERG, B. (1979). The effect of pyrophosphate analogues on influenza virus RNA polymerase and influenza virus replication. Arch. Virol., 61, 245–250.
STUART-HARRIS, C.H. (1981). The epidemiology and prevention of influenza. Am. Scient., 69, 166–172. STUART-HARRIS, C.H. & SCHILD, G.C. (1976) In Influenza, the virus and the Disease, London: Edward Arnold.
SWALLOW, D.L. (1978). Antiviral agents. Progr. Drug. Res., 22, 267–326.
TILLETT, H.E., SMITH, J.W.G. & CLIFFORD, R.E. (1980). Excess morbidity and mortality associated with influenza in England and Wales. Lancet, i, 793–795.
VARGHESE, J.N., LAVER, W.G. & COLMAN, P.M. (1983). Structure of the influenza virus glycoprotein antigen neuraminidase at 2–9 A resolution. Nature, 303, 35.
VAN VORIS, L.P., BETTS, R.F., HAYDEN, F.G., CHRISTMAS, W.A. & DOUGLAS, R.G., JR. (1981). Successful treatment of naturally occurring influenza A/USSR/77 HINI. J. Am. med. Ass., 245, 1128–1131.
WEBSTER, R.G., LAVER, W.G., AIR, G.M. & SCHILD, G.C. (1982). Molecular mechanisms of variation in influenza viruses. Nature, 296, 115.
WERNER, G.H. (1966). Immunité croisée Hétérotypique chez la souris entrevirus grippaux humains de types A et A2. C.R. Acad. Paris, 263, 1913–1916.
WHITE, J., KARTENBECK, J. & HELENIUS, A. (1982). Membrane fusion activity of influenza virus, EMBO Journal, 1, 217.
WORLD HEALTH ORGANISATION (1984). A programme for controlling acute respiratory infections in children: memorandum from a WHO meeting. Bull. Wld. Hlth. Org., 62, 47–58.
WILEY, D.C., WILSON, I.A. & SKEHEL, J.J. (1981). Structural identification of the antibody binding sites of the Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature, 298, 373.
WILSON, I.A., SKEHEL, J.J. & WILEY, D.C. (1981). The haemagglutinin membrane glycoprotein of influenza virus: structure at 3 A resolution. Nature, 289, 366.
YOUNKIN, S.W., BETTS, R.F., ROGH, F.K. & DOUGLAS, R.G., JR. (1983). Reduction in fever and symptoms in young adults with Influenza A/Brazil/78 HINI infection after treatment with aspirin or amantadine. Antimicrob. Ag. Chemo., 23, 577–582.
ZLYDNIKOV, D.M., KUBAR, O.I., KOVALEVA, R.P. & KAMFORIN, L.E. (1981). Study of rimantadine in the USSR: a review of the literature. Rev. Inf. Dis., 3, 408–421.
Author information
Authors and Affiliations
Editor information
Copyright information
© 1984 Macmillan Publishers Limited
About this chapter
Cite this chapter
Oxford, J.S. (1984). Control of epidemic influenza virus: aspects of vaccines and antiviral compounds. In: Paton, W., Mitchell, J., Turner, P. (eds) IUPHAR 9th International Congress of Pharmacology London 1984. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-17613-7_38
Download citation
DOI: https://doi.org/10.1007/978-1-349-17613-7_38
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-0-333-37134-3
Online ISBN: 978-1-349-17613-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)